Own products (APIs) for the generic pharmaceutical industry.
We provide quality products and services, consistently,
reliably responsibly and continuously applying some of the world’s
most difficult to handle chemical technologies.
Our independent one-site,
single entity corporate setup enables
Synthesis: Manufacturing services and products for all user industries,
using Archimica´s highly differentiated setup and technologies
APIs, Building blocks, GMP intermediates, Regulatory Starting Materials
For all global markets including the United States of America,
in total Archimica products reach 25 countries.
Founded in 2013, BioAscent is a leading provider of integrated drug discovery services. Our expert scientists provide medicinal chemistry, in vitro biosciences and compound management services from our base in the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland, and via Compound Cloud we offer access to an IP-free compound library in assay ready format.
Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management (>100 biochemical and biophysical assays established for drug discovery projects, >50 hit validation/characterisation projects, and >25 hit-to-lead campaigns since 2013). Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications.
We currently hold and manage over 1 million compounds for our customers in our €20 million facility, storing and managing customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats. We constantly receive and aggregate new compounds from our customers and their chemistry CRO partners, and ship in the assay-ready format of choice to their screening laboratories
Via our Compound Cloud service, we provide rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Our expertise in cherry picking, reformatting, shipping and data management have allowed us to deliver over 80,000 screening plates globally to our customers and their partner testing laboratories since 2013.
We are located in modern purpose-built laboratories on a single site, the former Organon / Merck Sharpe and Dohme (MSD) research & development facility, based within the BioCity Scotland campus at Newhouse, Scotland, UK.
Cerbios is a swiss privately held company specialized in the development and manufacturing of chemical and biological APIs for its world-wide partners.
The exclusive R&D and manufacturing expertise is available to our Pharma partners needing to develop and scale-up NCE or NBE for clinical trials, registration and commercial purpose.
cGMP APIs made by Cerbios in its FDA inspected site in Switzerland are sold worldwide mainly to pharma companies including EU, USA and Japan.
Cerbios is specialized in Reduced Folates (world leader position) but also in the manufacturing of High Potency Active Ingredients (HPAPIs) with a series of Vitamin D derivatives requiring sophisticated production units with high containment levels.
Another core business is the research, development and production of Probiotics of Pharma quality.
On top of that, in the last 17 years, CERBIOS has acquired a vast experience with Recombinant Proteins from mammalian cells (CHO) based on a state-of-the-art platform.
Service for third parties in exclusive manufacturing is concentrated in the area of HPAPI and Recombinant Proteins.
Full CMC support is given to our customers in order to provide them with the supply of cGMP clinical batches, registration/validation material and commercial manufacturing. Paramount to that is the supply of all documentation required for a successful registration.
For the total GMP synthesis of complex carbohydrates and carbohydrate based medicinal chemistry, Dextra has a proven record of developing innovative solutions to minimise costs, reduce technology transfer issues and optimise robust route generation.
Custom Synthesis—from mgs to multi kg scale, core capabilities include: Process development, glycosylation, hydrogenation and conjugation chemistry.
Analytical Services—providing comprehensive analytical support for custom synthesis programs and independent analytical services
GMP API Manufacturing—to support Phase I and Phase II clinical trials in reactors up to 50 L
Dextra Catalogue—showcases a range of over 800 carbohydrate products, including neoglycoproteins, neoglycolipids, heparin derivatives, iminosugars, blood group products, oligosaccharides, glycans, building blocks and a range of rare sugars for glycobiology and reference standards.
Dextra also has the ability to transfer complex chemical processes to its large scale manufacturing parent, New Zealand Pharmaceuticals.
DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical, biotech, and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 105 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, and reduce waste.
The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.
DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development, clear and transparent data and process documentation, and close customer communication.